Please login to the form below
autoimmune conditions
This page shows the latest autoimmune conditions news and features for those working in and with pharma, biotech and healthcare.
Enzyvant and Altavant announce merger to accelerate rare disease therapies
Children with congenital athymia can face repeated infections and may also be affected by autoimmune conditions, both of which can be fatal. ... Patients and families facing very serious and difficult-to-treat rare conditions are the inspiration for our
Latest news
-
Bristol Myers Squibb’s Opdualag approved by CHMP for melanoma
However, patients with active autoimmune disease, medical conditions needing systemic treatment with moderate or high dose corticosteroids or immunosuppressive medications, uveal melanoma and active or untreated brain or leptomeningeal metastases
-
WHO to test three more potential COVID-19 treatments
The third drug, Johnson &Johnson’s Remicade (infliximab), has been used to treat autoimmune inflammatory conditions for more than 20 years, including Crohn’s Disease and rheumatoid arthritis.
-
US Supreme Court rebuffs Sandoz’s Enbrel biosimilar patent case
Today’s decision means Erelzi, a more affordable biosimilar, will not be available to US patients with autoimmune and inflammatory diseases until 2029; nonetheless we remain committed to providing important treatment ... Enbrel, which yielded
-
Sanofi pays $160m upfront to acquire Tidal Therapeutics
We believe that the underlying mRNA targeting platform will create disruptive therapeutic approaches across a variety of oncology and autoimmune conditions,” he added.
-
Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors
Lilly will co-develop and commercialise R552 across all indications, including autoimmune and inflammatory diseases. ... At Lilly, our immunology strategy is focused on the pursuit of novel targets that have the potential to develop into best-in-class
More from news
Approximately 2 fully matching, plus 23 partially matching documents found.
Latest Intelligence
-
How early-stage clinical research is facilitating the new wave of personalised medicines
is also being used to treat autoimmune and cardiac conditions, and biologic medicines, which now account for 15% of medicines prescribed in Japan and 30% in the USA (in 2018). ... as the technology is tested in more conditions and biomarkers.
-
Piloting a route to the biosimilars opportunities in Europe
Biological medicines represent a major advance in the treatment of serious pathological conditions such as cancer, neurodegenerative and autoimmune diseases, in the form of biosimilars.
-
Managing medication non-adherence
Autoimmune conditions such as Crohn’s disease can flare up through an imbalance of things like stress, lack of sleep or overworking - not just as a direct consequence of nonadherence to ... The latter is a vital service for patients with chronic
-
Taking a lean and careful approach
This fits well with our mission to tackle unmet needs. Autoimmune conditions are increasing and diabetes is at epidemic levels. ... A lot of NASH patients also have these conditions so we want to look at and understand the underlying causes to see what
-
Deal Watch table for April 2014
7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Former Sanofi SVP to chair Idera
Idera specialises in developing toll-like receptors (TLRs) for autoimmune and inflammatory conditions and will benefit from Geraghty's extensive career in the life sciences industry, which includes 20 years ion ... conditions. 19th July 2013.
-
Teva appoints chief strategy officer
Prior to this, he was president and CEO of Cerimon Pharmaceuticals, a biopharma focused on autoimmune conditions and pain management.
-
AIMM Therapeutics appoints former Novartis VP Jan de Vries as CEO
and autoimmune conditions. ... multiple sclerosis and secukinumab for several inflammatory conditions.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Page & Page and Partners
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
